- Home
- ATNF vs QNRX Comparison
ATNF vs QNRX Comparison
Compare ATNF & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- QNRX
- Stock Information
- Founded
- ATNF 2016
- QNRX 2018
- Country
- ATNF United States
- QNRX United States
- Employees
- ATNF N/A
- QNRX N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- ATNF Health Care
- QNRX Health Care
- Exchange
- ATNF Nasdaq
- QNRX Nasdaq
- Market Cap
- ATNF 1.8M
- QNRX 2.1M
- IPO Year
- ATNF N/A
- QNRX N/A
- Fundamental
- Price
- ATNF $1.42
- QNRX $0.48
- Analyst Decision
- ATNF
- QNRX Strong Buy
- Analyst Count
- ATNF 0
- QNRX 1
- Target Price
- ATNF N/A
- QNRX $4.00
- AVG Volume (30 Days)
- ATNF 46.0K
- QNRX 1.4M
- Earning Date
- ATNF 11-07-2024
- QNRX 11-06-2024
- Dividend Yield
- ATNF N/A
- QNRX N/A
- EPS Growth
- ATNF N/A
- QNRX N/A
- EPS
- ATNF N/A
- QNRX N/A
- Revenue
- ATNF N/A
- QNRX N/A
- Revenue This Year
- ATNF N/A
- QNRX N/A
- Revenue Next Year
- ATNF $54.15
- QNRX N/A
- P/E Ratio
- ATNF N/A
- QNRX N/A
- Revenue Growth
- ATNF N/A
- QNRX N/A
- 52 Week Low
- ATNF $1.31
- QNRX $0.48
- 52 Week High
- ATNF $12.03
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- ATNF 35.64
- QNRX 39.02
- Support Level
- ATNF $1.38
- QNRX $0.48
- Resistance Level
- ATNF $1.58
- QNRX $0.55
- Average True Range (ATR)
- ATNF 0.16
- QNRX 0.03
- MACD
- ATNF -0.05
- QNRX -0.01
- Stochastic Oscillator
- ATNF 4.60
- QNRX 2.60
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.